| Browse All

Precigen, Inc. (PGEN)

Healthcare | Biotechnology | Germantown, United States | NasdaqGS
3.98 USD -0.13 (-3.163%) ⇩ (April 21, 2026, 4 p.m. EDT)

Short-term:★★★☆☆Long-term:★☆☆☆☆Dividends:☆☆☆☆☆
Hot Take | April 18, 2026, 10:23 p.m. EDT

PGEN is a high-octane biotech gamble with unlimited bust risk due to non-revenue status and massive short-term put concentration at critical support levels. While the commercial transition of respiratory papillomatosis treatments with $9.5M analysts targets sounds compelling, the current trade is a net put-heavy setup waiting for a catalyst. Until the massive July put pressure at $3 strikes is azed or increasing revenue clears the gap, any rally is likely to be chopped up by profit-taking at the put wall.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
MSTL ✓0.186666
AutoARIMA0.192171
AutoETS0.192171
AutoTheta0.220644

Forecast horizon: 45 days | Selected: MSTL

Forecast Reliability
Score 44%
H-stat 8.93
Ljung-Box p 0.000
Jarque-Bera p 0.354
Excess Kurtosis -1.04
Attribute Value
Sector Healthcare
Debt to Equity Ratio 470.04
Revenue per Share 0.031
Market Cap 1,408,636,160
Forward P/E -18.09
Beta 1.12
Website https://precigen.com

As of April 18, 2026, 10:23 p.m. EDT: Market sentiment is heavily skewed towards downside protection despite the stock trading near recent highs. May 2026 calls show strong Open Interest (OTM) at $4.50 and $5.00, indicating a bullish thesis for a continued run. However, the Put Writers' Put (PWP) data for July 2026 is alarming, with massive OI (15.3k contracts) at the $3.00 strike. This creates a significant limit-down risk if the stock retraces to the 1-year low near $1.23, triggering a put wall. Implied Volatility is elevated (117%+), suggesting the market anticipates a high-risk event or earnings gap.


Info Dump

Attribute Value
52 Week Change 1.4567902
Address1 20,374 Seneca Meadows Parkway
All Time High 68.83053
All Time Low 0.65
Ask 4.01
Ask Size 6
Audit Risk 6
Average Daily Volume10 Day 2,966,730
Average Daily Volume3 Month 4,571,349
Average Volume 4,571,349
Average Volume10Days 2,966,730
Beta 1.124
Bid 3.93
Bid Size 5
Board Risk 6
Book Value 0.059
City Germantown
Compensation As Of Epoch Date 1,735,603,200
Compensation Risk 6
Country United States
Crypto Tradeable 0
Currency USD
Current Price 3.98
Current Ratio 3.089
Custom Price Alert Confidence HIGH
Date Short Interest 1,774,915,200
Day High 4.115
Day Low 3.94
Debt To Equity 470.04
Display Name Precigen
Earnings Call Timestamp End 1,774,470,600
Earnings Call Timestamp Start 1,774,470,600
Earnings Timestamp 1,774,468,800
Earnings Timestamp End 1,778,788,800
Earnings Timestamp Start 1,778,788,800
Ebitda -103,401,000
Ebitda Margins 0.0
Enterprise To Ebitda -13.627
Enterprise To Revenue 145.505
Enterprise Value 1,409,068,160
Eps Forward -0.22
Eps Trailing Twelve Months -1.37
Esg Populated 0
Exchange NMS
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 3.8924
Fifty Day Average Change 0.08759999
Fifty Day Average Change Percent 0.022505393
Fifty Two Week Change Percent 145.67902
Fifty Two Week High 5.47
Fifty Two Week High Change -1.4899998
Fifty Two Week High Change Percent -0.27239484
Fifty Two Week Low 1.23
Fifty Two Week Low Change 2.75
Fifty Two Week Low Change Percent 2.2357724
Fifty Two Week Range 1.23 - 5.47
Financial Currency USD
First Trade Date Milliseconds 1,375,968,600,000
Float Shares 168,884,144
Forward Eps -0.22
Forward P E -18.09091
Free Cashflow -53,353,876
Full Exchange Name NasdaqGS
Full Time Employees 160
Gmt Off Set Milliseconds -14,400,000
Governance Epoch Date 1,775,001,600
Gross Margins 0.0
Gross Profits -36,472,000
Has Pre Post Market Data 1
Held Percent Insiders 0.13934
Held Percent Institutions 0.73148
Implied Shares Outstanding 353,928,672
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Long Business Summary Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis. Further, it provides UltraPorator, a proprietary electroporation device. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
Long Name Precigen, Inc.
Market us_market
Market Cap 1,408,636,160
Market State PRE
Max Age 86,400
Message Board Id finmb_22365961
Most Recent Quarter 1,767,139,200
Net Income To Common -429,641,984
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 1,408,636,114
Number Of Analyst Opinions 2
Open 4.09
Operating Cashflow -87,831,000
Operating Margins -4.74611
Overall Risk 4
Payout Ratio 0.0
Phone 301 556 9900
Pre Market Change -0.11000013
Pre Market Change Percent -2.7638226
Pre Market Price 3.87
Pre Market Time 1,776,844,815
Previous Close 4.11
Price Hint 4
Price To Book 67.45763
Price To Sales Trailing12 Months 145.46016
Profit Margins 0.0
Quick Ratio 2.74
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change -0.13
Regular Market Change Percent -3.16302
Regular Market Day High 4.115
Regular Market Day Low 3.94
Regular Market Day Range 3.94 - 4.115
Regular Market Open 4.09
Regular Market Previous Close 4.11
Regular Market Price 3.98
Regular Market Time 1,776,801,600
Regular Market Volume 1,607,173
Return On Assets -0.44303
Return On Equity -5.7196803
Revenue Growth 2.836
Revenue Per Share 0.031
Sand P52 Week Change 0.3140242
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Share Holder Rights Risk 3
Shares Outstanding 353,928,672
Shares Percent Shares Out 0.1121
Shares Short 39,661,787
Shares Short Previous Month Date 1,772,150,400
Shares Short Prior Month 41,882,137
Short Name Precigen, Inc.
Short Percent Of Float 0.1733
Short Ratio 7.03
Source Interval 15
State MD
Symbol PGEN
Target High Price 10.0
Target Low Price 9.0
Target Mean Price 9.5
Target Median Price 9.5
Total Cash 97,858,000
Total Cash Per Share 0.276
Total Debt 98,290,000
Total Revenue 9,684,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -1.37
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 3.6536
Two Hundred Day Average Change 0.32640004
Two Hundred Day Average Change Percent 0.08933656
Type Disp Equity
Volume 1,607,173
Website https://precigen.com
Zip 20,876